Treatment with epigenetic modulators increases effector T cell infiltration, represses tumor progression, and promotes the therapeutic efficacy of PD-L1 checkpoint blockade in prostate or head and neck cancer (68, 69). This evidence concerns the gene CD274 and neoplasm.